Journal Information
Most often read
918
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative ColitisFrancisco Rodríguez-Moranta, Federico Argüelles-Arias, Joaquín Hinojosa del Val, Marisa Iborra Colomino, M. Dolores Martín-Arranz, Luis Menchén Viso, Fernando Muñoz Núñez, Elena Ricart Gómez, ... Ana Gutiérrez Casbas
Gastroenterol Hepatol. 2024;47:522-52
918
Full text access
Open Article
380
Asociación Española de Neurogastroenterología y Motilidad (ASENEM) updated review on the management of functional abdominal painJordi Serra, Ariadna Aguilar, Elizabeth Barba, Constanza Ciriza de los Ríos, Laura Garcia Pravia, Vicente Martínez, Blanca Serrano Falcón
Gastroenterol Hepatol. 2024;47:888-900
380
Full text access
Open Article
331
Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis on sexuality and inflammatory bowel diseaseMarta Calvo Moya, Francisco Mesonero Gismero, Cristina Suarez Ferrer, Alejandro Hernández-Camba, Danízar Vásquez Carlón, Fátima García Benasach, Mariam Aguas Peris, Francisco José Delgado Oliva, ... on behalf of GETECCU
Gastroenterol Hepatol. 2024;47:774-92
331
Full text access
Open Article
312
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCUMar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, ... María-Carlota Londoño
Gastroenterol Hepatol. 2024;47:401-32
312
Full text access
Open Article
303
Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: Results of a Delphi studyRocío Aller, José Luis Calleja, Javier Crespo, Manuel Romero-Gómez, Juan Turnes, Omar J. Benmarzouk-Hidalgo, Rafael Subirán, Alicia Gil
Gastroenterol Hepatol. 2024;47:337-46
303
Full text access
Open Article
298
Recommendations and quality criteria to improve the early diagnosis of primary biliary cholangitisÁlvaro Díaz-González, Noelia Fontanillas, Eva Gil-Hernández, Mercedes Guilabert, Maria-Carlota Londoño, Mar Noguerol, Fernando Pérez Escanilla, José J. Mira, Manuel Santiñá
Gastroenterol Hepatol. 2024;47:834-44
298
Full text access
Open Article
257
Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processingJose Luis Calleja-Panero, Rafael Esteban Mur, Isidro Jarque, Manuel Romero-Gómez, Savana Research Group, Lucia García Labrador, Jose González Calvo
Gastroenterol Hepatol. 2024;47:236-45
257
Full text access
Open Article
237
Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish Society of Digestive Endoscopy (SEED)Eugeni Domènech, Andreea Ciudin, José María Balibrea, Eduard Espinet-Coll, Fiorella Cañete, Lilliam Flores, Manuel Ferrer-Márquez, Román Turró, ... on behalf of the GETECCU-SEEDO-AEC-SEED Consensus Group
Gastroenterol Hepatol. 2024;47:906-23
237
Full text access
Open Article
231
Prognostic value of abnormal liver function test for hospitalized patients with COVID-19Carlos Alventosa Mateu, Salvador Benlloch, Moisés Diago
Gastroenterol Hepatol. 2024;47:192-3
231
223
Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM studyDomingo Balderramo, Jesús Yamamoto-Furusho, Enrique Ponce de León, Julio de María, Ignacio Zubiaurre, Silvia Pedreira, Camilo Lis, Laura Brion, Juan A. de Paula
Gastroenterol Hepatol. 2024;47:51-62
223
Full text access
Open Article
219
Enteric duplication cyst as a rare presentation of adult acute abdomenGerard Rafart, Clara Bassaganyas, Xavier Morales, Míriam Cuatrecasas, Jordi Rimola
Gastroenterol Hepatol. 2024;47:389-90
219
Full text access
Open Article
187
An in vitro analysis of the interaction between infliximab and granulocyte–monocyte apheresisIago Rodríguez-Lago, Leticia Abecia, Iratxe Seoane, Juan Anguita, José Luis Cabriada
Gastroenterol Hepatol. 2024;47:347-51
187
Full text access
Open Article
166
Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN studyAnum Shaikh, Gabriel Pedra, Leonardo Ruiz-Casas, Bethany Franks, Harpal Dhillon, João Diogo da Rocha Fernandes, Kamal Kant Mangla, Margarida Augusto, ... Jörn M. Schattenberg
Gastroenterol Hepatol. 2024;47:463-72
166
Full text access
Open Article
153
Granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease: A useful therapeutic tool not just in ulcerative colitis but also in Crohn's diseaseFrancisco José Fernández-Pérez, Nuria Fernández-Moreno, Estela Soria-López, Francisco Javier Rodriguez-González, Francisco José Fernández-Galeote, Ana Lifante-Oliva, Concepción Ruíz-Hernández, Elisabeth Escalante-Quijaite, Francisco Rivas-Ruiz
Gastroenterol Hepatol. 2024;47:502196
153
Full text access
Open Article
149
Rspo2-LGR4 exacerbates hepatocellular carcinoma progression via activation of Wnt/β-catenin signaling pathwayYanghui Bi, Liping Zhang, Yan Song, Lijun Sun, Michael W. Mulholland, Yue Yin, Weizhen Zhang
Gastroenterol Hepatol. 2024;47:352-65
149
Full text access
Open Article
146
Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease—EXVEDOCOLViviana Parra, Sandra Cifuentes, Sandra Avendaño, Enrique Ponce de León, Cristian Florez, Gustavo Reyes, Fabian Puentes, Manuel Ballesteros, ... Juan Ricardo Márquez
Gastroenterol Hepatol. 2024;47:858-66
146
Full text access
Open Article
142
Black esophagus: Massive bleeding in cirrhosis does not always mean variceal ruptureVítor Macedo Silva, Ana Isabel Ferreira, Pedro Boal Carvalho, Joana Magalhães, José Cotter
Gastroenterol Hepatol. 2024;47:504-5
142
Full text access
Open Article
134
Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, Belén Beltrán, Eugeni Domènech, Ana Gutiérrez Casbas, Miriam Mañosa, Yamile Zabana, ... Santiago García-López
Gastroenterol Hepatol. 2024;47:750-8
134
130
Management of colorectal cancer screening backlog due to the COVID-19 pandemic: A retrospective analysis of the use of a colorectal cancer screening clinical-decision support tool in ArgentinaLisandro Pereyra, Leandro Steinberg, Juan Lasa, Agustina Marconi, Audrey H. Calderwood, María Pellisé
Gastroenterol Hepatol. 2024;47:140-8
130
113
Selective granulocyte–monocyte apheresis during induction with vedolizumab in moderate–severe ulcerative colitis: Experience in a tertiary hospitalCristina Suárez Ferrer, Eduardo Martin-Arranz, María Dolores Martín-Arranz
Gastroenterol Hepatol. 2024;47:721-6
113
Full text access
Open Article